Stock 1477 OCUMENSION THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ocumension Therapeutics

Equities

1477

KYG674111011

Delayed Hong Kong S.E.
Other stock markets
 02:36:06 29/04/2024 BST 		5-day change 1st Jan Change
6.55 HKD +1.24% Intraday chart for Ocumension Therapeutics +12.16% -1.95%
04-15 Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug MT
04-15 Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023
Ocumension Therapeutics Reports Earnings Results for the Half Year Ended June 30, 2023
Ocumension Therapeutics Announces patient Enrollment Completed in the Real-World Study of OT-502 in Hainan Boao
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101
Ocumension Therapeutics Provides Update on OT-1001
Nicox: trésorerie de 21,4 millions d’euros à fin mars, visibilité jusqu’au deuxième trimestre 2024
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1477 Stock
  4. News Ocumension Therapeutics
  5. Other languages